Progress Software (NASDAQ: PRGS), Seattle Genetics, Inc. (NASDAQ: SGEN), Amylin Pharma (NASDAQ: AMLN), Rent-A-Center, Inc. (NASDAQ: RCII), Rambus Inc. (NASDAQ: RMBS) and Take-Two (NASDAQ: TTWO) ratings and price targets.
Progress Software (PRGS) had its “Buy” rating reiterated by Needham & Company.
Seattle Genetics, Inc. (SGEN) had its “Sell” rating reiterated by Canaccord Genuity.
Amylin Pharma (AMLN) is now covered by Rodman & Renshaw. They placed an “Underperform” rating and a price target of $8.00 on the company.
Rent-A-Center, Inc. (NASDAQ: RCII) had its “Neutral” rating reiterated by Zacks Investment Research. They have a price target of $39.00 on the company.
Rambus Inc. (RMBS) had its “Neutral” rating reiterated by JPMorgan Chase & Co. (NYSE:JPM). They have a price target of $11.50 on the company.
Take-Two (TTWO) was upgraded by MKM Partners from a “Neutral” rating to a “Buy” rating. They have a price target of $20.00 on the company, up from $16.00.
No comments:
Post a Comment